Beckman Research Institute of the City of Hope
$100,000 Tower Career Development Grant
Research Title:
Translational Development of a Novel CD30 Bispecific Antibody
Bispecific antibodies are a new class of immunotherapies that activate the immune system to target and kill cancer cells. Currently, bispecific antibodies are approved to treat lymphomas that express a specific protein called CD20. Many lymphomas, however, are CD20-negative and new bispecific targets for these cancers. Here we are developing a new bispecific antibody against CD30 within this application so the benefits of bispecific antibodies can also be realized for patients with CD20-negative lymphomas.